Research Analysts Offer Predictions for NKTR FY2024 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Nektar Therapeutics in a report released on Tuesday, December 10th. HC Wainwright analyst A. He expects that the biopharmaceutical company will post earnings of ($0.46) per share for the year. HC Wainwright has a “Buy” rating and a $6.50 price objective on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q4 2024 earnings at $0.13 EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.15) EPS.

Several other research firms also recently weighed in on NKTR. BTIG Research restated a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a report on Monday, September 30th. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $4.10.

Nektar Therapeutics Stock Up 1.0 %

NASDAQ:NKTR opened at $1.01 on Thursday. Nektar Therapeutics has a 52-week low of $0.46 and a 52-week high of $1.93. The stock has a fifty day simple moving average of $1.21 and a 200-day simple moving average of $1.25. The company has a market capitalization of $186.30 million, a PE ratio of -1.20 and a beta of 0.57.

Hedge Funds Weigh In On Nektar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of NKTR. SG Americas Securities LLC grew its stake in Nektar Therapeutics by 63.0% in the 2nd quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock worth $91,000 after acquiring an additional 28,338 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Nektar Therapeutics during the second quarter worth $56,000. Bank of New York Mellon Corp grew its position in shares of Nektar Therapeutics by 2,822.5% in the second quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 532,663 shares during the period. Rhumbline Advisers increased its stake in Nektar Therapeutics by 3,377.0% in the second quarter. Rhumbline Advisers now owns 185,116 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 179,792 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Nektar Therapeutics during the second quarter worth about $29,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.